NASDAQ:OVIDOvid Therapeutics Stock Price, Forecast & News

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 96.1% and is now trading at $5.2550. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ovid Therapeutics.

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Ovid Therapeutics.

Ovid Therapeutics Inc (NASDAQ:OVID) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.04. View Ovid Therapeutics' earnings history.

6 brokerages have issued 1 year price targets for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $20.00. On average, they expect Ovid Therapeutics' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 166.4% from the stock's current price. View analysts' price targets for Ovid Therapeutics.

Media stories about OVID stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ovid Therapeutics earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutOvid Therapeutics.

Ovid Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,650,000 shares, an increase of 20.4% from the April 30th total of 1,370,000 shares. Based on an average trading volume of 602,000 shares, the short-interest ratio is currently 2.7 days. Approximately 5.7% of the shares of the company are short sold. View Ovid Therapeutics' Current Options Chain.

Some companies that are related to Ovid Therapeutics include Constellation Pharmaceuticals (CNST), Passage Bio (ZNTL), Intra-Cellular Therapies (ITCI), Portola Pharmaceuticals (PTLA), ZEALAND PHARMA/S (ZEAL), Karyopharm Therapeutics (KPTI), Tricida (TCDA), Phoenix Tree (IMAB), Supernus Pharmaceuticals (SUPN), Cytokinetics (CYTK), Phathom Pharmaceuticals (PHAT), Revance Therapeutics (RVNC), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX) and I-Mab (ARQT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Anavex Life Sciences (AVXL), Enphase Energy (ENPH) and Johnson & Johnson (JNJ).

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include AXA (1.49%), BlackRock Inc. (0.89%), Wells Fargo & Company MN (0.89%), Ikarian Capital LLC (0.69%), Geode Capital Management LLC (0.54%) and UBS Group AG (0.38%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View institutional ownership trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, JPMorgan Chase & Co., Acadian Asset Management LLC, Blair William & Co. IL, EAM Investors LLC, AXA, and Squarepoint Ops LLC. View insider buying and selling activity for Ovid Therapeutics.

OVID stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Connor Clark & Lunn Investment Management Ltd., Assenagon Asset Management S.A., Jane Street Group LLC, BlackRock Inc., Wedbush Securities Inc., Ikarian Capital LLC, and Shufro Rose & Co. LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda. View insider buying and selling activity for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $5.26.

Ovid Therapeutics has a market capitalization of $287.73 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 59 workers across the globe.

The official website for Ovid Therapeutics is www.ovidrx.com.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]